Dr. Mark Pegram & Dr. Ana Garrido-Castro – Breakthrough Data in Metastatic TNBC

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/a8/e9/5f/a8e95f8b-aa1d-fc10-a97d-970ed536395a/mza_6256469873985417328.jpg/600x600bb.jpg

Community Health Media

15 episodes

6 days ago

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences. We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcasts

Medicine

Health & Fitness

RSS

All content for Community Health Media is the property of Community Health Media and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/42498441/42498441-1764590876723-e5a8503719dda.jpg

Dr. Mark Pegram & Dr. Ana Garrido-Castro – Breakthrough Data in Metastatic TNBC

Community Health Media

32 minutes 20 seconds

1 month ago

Dr. Mark Pegram & Dr. Ana Garrido-Castro – Breakthrough Data in Metastatic TNBC

At ESMO Berlin, Dr. Mark Pegram and Dr. Ana Garrido-Castro break down breakthrough data shaping the new standard for first-line metastatic triple-negative breast cancer (TNBC).

Together, they unpack results from ASCENT-03 and TROPION-Breast02, where Trop-2 antibody-drug conjugates demonstrated significant improvements in response rates, PFS, and — in one study — overall survival.

Drs. Pegram and Garrido-Castro explore:

• Why Trop-2 ADCs may replace chemotherapy in PD-L1–negative TNBC

• Key differences in trial design, patient selection, and endpoints

• Real-world decision-making based on toxicity, dosing schedules, and prophylaxis

• How HR-low disease, BRCA/PALB2 status, and CNS involvement factor into treatment strategy

A must-listen for clinicians navigating the fast-evolving landscape of metastatic TNBC and the rise of ADC-driven precision therapy.

#BreastCancer #TNBC #TripleNegativeBreastCancer #ESMO2025 #OncologyPodcast #Trop2 #ADCtherapy #CancerResearch #ClinicalOncology #BreastOncology #PrecisionOncology #CHM

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media